1Miyasaka Y,Barnes ME,Gersh BJ,et al.Secular trends in incidence of atrial fibrillation in Olmsted County,Minnesota,1980 to 2000,and implications on the projections for future prevalence.Circulation,2006,114:119-125.
2Levys Factors Predisposing to the development of atrial fibrillation.PACE,1997,20:2670-2674.
6Madrid AH,Bueno MC,Rebollo JMC,et al.Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrialfi-brillation:A prospective and randomized study[J].Circulation,2002,106:331.
1Van den Berg MP,Crijns HJGM, Van veldhuisen DJ,et al.Effects of lisinopril in patient with heart failure and chronic atrial fibrillation. J Card Failure, 1995,1: 355-363.
2Pedersen OD,Bagger H,Kober L,et al. Trandolapril reduces the incidence of atrial fibrillation after acure myocardial infarction in patients with left ventricular dysfunction. Circulation, 1999,100: 376-380.
3Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol,2000,35: 1669-1677.
4Rogg H,de Gasparo M,Graedel E,et al. Angiotensin Ⅱ-receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction. Eur Heart J, 1996,17:1112-1120.
5Asano K, Dutcher DL, Port JD, et al. Selective downregulation of the angiotensin Ⅱ AT1-receptor subtype in failing human ventricular myocardium. Circulation, 1997,95: 11931200.
6Matsubara H. Pathophysiological role of angiotensin Ⅱ type 2 receptor in cardiovascular and renal diseases. Circ Res,1998,83:1182-1191.
7Goette A,Amdt M,Rocken C,et al. Regulation of angiotension Ⅱ receptor subtypes during atrial fibrillation in humans. Circulation, 2000,101: 2678-2781.
4DUCHARME A,SWEDBERG K, PFEFFER M A, et al.prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure : assessment of Reduc- tion in Mortality and morbidity (CHARM)program [J].Am Heart J, 2006,151 : 985-991.
5Hailer H, ho S, Izzo JL Jr, et al.olmesartan for the delay or prevention of Mieroalbuminuria in type 2 diabetes [J].N Engl J Meal,2011,364 (10) :907-917.
